Genmab — Oktober 2020
-
-
-
Tusinde tak SEACOP.
-
I noticed on this Korean site -which is part of the Ministry of Food and Drug Safety- a refecence to Epcoritamab, which, upon translating reads "Randomized, open-label, phase 3 clinical trial comparing epcoritamab with investigator-selected chemotherapy in relapsed/refractory diffuse large B-cell lymphoma"
-
-
IQvia is a Data Science company, I know they deal with AbbVie, I don't know if they also provide assistence in trial management ? https://www.iqvia.com/blogs/2020/02/will-virtual-trials-be-the-end-of-investigator-sites
-
Thank you E L. Jan mentioned at the latest fireside chat, that epcoritamab could potentially eleminate chemotherapy. This might be one of the steps to prove that...
-
and this link seems to indicate that Amivantamab has entered a breakthrough therapy program in China https://xueqiu.com/8965749698/161088590
-
Servicemeddelelse: Vi arbejder på sitet i aften og nat. Beklager kortvarige udfald.
-
God morgen.
-
Treating Relapsed and/or Refractory Multiple Myeloma in the Complex Treatment Landscape
https://ashpublications.org/thehematologist/article/464323/Treating-Relapsed-and-or-Refractory-Multiple
Hvis! - så skal vi kigge grundigt over skulderen for at skimte 3.000 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind